Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

Erstveröffentlichung
2013
Metadata only
Search for full text

Wissenschaftlicher Artikel

Authors
Kampa-Schittenhelm, Kerstin Maria
Heinrich, Michael Charles
Akmut, Figen
Döhner, Hartmut
Doehner, Konstanze
et al.
Institutions
UKU. Klinik für Innere Medizin III
Published in
Molecular cancer ; 12 (2013). - Art.-Nr. 19. - ISSN 1476-4598
Link to publication
https://dx.doi.org/10.1186/1476-4598-12-19
Funding information
Deutsche Krebshilfe Foundation
IZKF Program of the Medical Faculty Tubingen
Carreras Scholarship Program
Leukemia and Lymphoma Society
Department of Veterans Affairs
etc.
Keywords
AC220; Quizartinib; Leukemia; KIT; FLT3; PDGFR; acute myeloid-leukemia; gastrointestinal stromal tumor; internal tandem duplications; ligand-independent activation; mast-cell leukemia; c-kit; myelodysplastic syndrome; flt3 gene; wild-type; systemic mastocytosis
Dewey Decimal Group
DDC 610 / Medicine & health
Metadata
Show full item record